Gankyrin: a new oncoprotein and regulator of pRb and p53

Trends in Cell Biology

Volumn 16, Issue 5, 2006, Pages 229-233

  Dawson, Simon ^a   Higashitsuji, Hiroaki ^b   Wilkinson, Anthony J ^c   Fujita, Jun ^b   Mayer, R John ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CYCLIN DEPENDENT KINASE 4; ONCOPROTEIN; PROTEASOME; PROTEIN GANKYRIN; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; DNA REPAIR; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

ANIMALS; ANKYRINS; HUMANS; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 33646542006     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcb.2006.03.001     Document Type: Article

References (46)

1. Sherr C.J. Principles of tumor suppression. Cell 116 (2004) 235-246
2. Quelle D.E., et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83 (1995) 993-1000
3. Macaluso M., et al. Modulation of cell cycle components by epigenetic and genetic events. Semin. Oncol. 32 (2005) 452-457
4. Devoy, A. et al. (2005) The ubiquitin proteasome system and cancer. In Essays in Biochemistry: The Ubiquitin Proteasome System (Vol. 41) (Layfield, R. and Mayer, R.J., eds.) Portland Press pp 187-203
5. Higashitsuji H., et al. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat. Med. 6 (2000) 96-99
6. Higashitsuji H., et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell 8 (2005) 75-87
7. Krzywda S., et al. The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53. J. Biol. Chem. 279 (2004) 1541-1545
8. Hori T., et al. cDNA cloning and functional analysis of p28 (Nas6p) and p40.5 (Nas7p), two novel regulatory subunits of the 26S proteasome. Gene 216 (1998) 113-122
9. Dawson S., et al. Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome. J. Biol. Chem. 277 (2002) 10893-10902
10. Guo F., et al. Crystal structure of ClpA, an HSP100 chaperone and regulator of ClpAP protease. J. Biol. Chem. 277 (2002) 46743-46752
11. Seeger M., et al. Characteristics of 26 S proteases from fission yeast mutants, which arrest in mitosis. J. Mol. Biol. 263 (1996) 423-431
12. Ferrell K., et al. Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem. Sci. 25 (2000) 83-88
13. Sdek P., et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell 20 (2005) 699-708
14. Li J., and Tsai M.D. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb. Biochemistry 41 (2002) 3977-3983
15. Verma R., et al. Proteasomal proteomics: identification of nucleotide-sensitive proteasome-interacting proteins by mass spectrometric analysis of affinity-purified proteasomes. Mol. Biol. Cell 11 (2000) 3425-3439
16. Welchman R.L., et al. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev. Mol. Cell Biol. 6 (2005) 599-609
17. Corn P.G., et al. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat. Genet. 35 (2003) 229-237
18. Upadhya S.C., and Hegde A.N. A potential proteasome-interacting motif within the ubiquitin-like domain of parkin and other proteins. Trends Biochem. Sci. 28 (2003) 280-283
19. Nagao T., et al. MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J. Biol. Chem. 278 (2003) 10668-10674
20. Kussie P.H., et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274 (1996) 948-953
21. Manjasetty B.A., et al. X-ray structure of human gankyrin, the product of a gene linked to hepatocellular carcinoma. Proteins 55 (2004) 214-217
22. Padmanabhan B., et al. Crystal structure of the homolog of the oncoprotein gankyrin, an interactor of Rb and CDK4/6. J. Biol. Chem. 279 (2004) 1546-1552
23. Yuan C., et al. Solution structure of the human oncogenic protein gankyrin containing seven ankyrin repeats and analysis of its structure-function relationship. Biochemistry 43 (2004) 12152-12161
24. Zheng N., et al. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102 (2000) 533-539
25. Xirodimas D.P., et al. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118 (2004) 83-97
26. Rodriguez M.S., et al. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18 (1999) 6455-6461
27. Krummel K.A., et al. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10188-10193
28. Feng L., et al. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 25 (2005) 5389-5395
29. Stommel J.M., and Wahl G.M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23 (2004) 1547-1556
30. Reid G., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 11 (2003) 695-707
31. Gonzalez F., et al. Recruitment of a 19S proteasome subcomplex to an activated promoter. Science 296 (2002) 548-550
32. Muratani M., and Tansey W.P. How the ubiquitin-proteasome system controls transcription. Nat. Rev. Mol. Cell Biol. 4 (2003) 192-201
33. Asher G., et al. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 19 (2005) 316-321
34. Uchida C., et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J. 24 (2005) 160-169
35. Josse L., et al. Fission yeast Dss1 associates with the proteasome and is required for efficient ubiquitin-dependent proteolysis. Biochem. J. 393 (2006) 303-309
36. Funakoshi M., et al. Sem1, the yeast ortholog of a human BRCA2-binding protein, is a component of the proteasome regulatory particle that enhances proteasome stability. J. Cell Sci. 117 (2004) 6447-6454
37. Krogan N.J., et al. Proteasome involvement in the repair of DNA double-strand breaks. Mol. Cell 16 (2004) 1027-1034
38. Marston N.J., et al. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol. Cell. Biol. 19 (1999) 4633-4642
39. Yang H., et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 297 (2002) 1837-1848
40. Gudmundsdottir K., et al. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep. 5 (2004) 989-993
41. Kojic M., et al. The BRCA2-interacting protein DSS1 is vital for DNA repair, recombination, and genome stability in Ustilago maydis. Mol. Cell 12 (2003) 1043-1049
42. Dong Y., et al. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. Mol. Cell. 12 (2003) 1087-1099
43. Fu X.Y., et al. Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J. Gastroenterol. 8 (2002) 638-643
44. Lim I.K. Spectrum of molecular changes during hepatocarcinogenesis induced by DEN and other chemicals in Fischer 344 male rats. Mech. Ageing Dev. 124 (2003) 697-708
45. Li H., et al. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. Gastroenterology 128 (2005) 2029-2041
46. Her G.M., et al. Imbalance in liver homeostasis leading to hyperplasia by overexpressing either one of the Bcl-2-related genes, zfBLP1 and zfMcl-1a. Dev. Dyn. 235 (2006) 515-523